Abbvie INC.

lobbying client · lobbying firm

Abbvie INC.'s federal footprint — reported lobbying spend and, where matched, federal money received. Figures are as reported to the U.S. Senate (LDA) and USAspending.

Lobbying from Senate LDA

Reported lobbying (spent)$26,960,000

Years coveredFY2022–FY2025

Reported lobbying billed / handled $21,990,000

Firm activeFY2022–FY2025

Reported country: 🇺🇸 United States

Lobbying over time

Reported lobbying for Abbvie INC. per filing year
FY	Lobbying spend (as client)	Lobbying billed / handled (as firm)
2022	$9,560,000	$8,200,000
2023	$4,790,000	$3,680,000
2024	$5,730,000	$4,530,000
2025	$6,880,000	$5,580,000

Two figures: what Abbvie INC. reported spending on its own lobbying (as a client) and what it billed or handled for the clients it represents (as a firm — revenue, not its own spend). For a self-filer these overlap.

Firms hired

Tarplin, Downs & Young, LLC $1,080,000 · 18 filings
Cornerstone Government Affairs, INC. $960,000 · 16 filings
Federal Street Strategies, LLC $800,000 · 16 filings
W Strategies, LLC $800,000 · 16 filings
Baker & Hostetler LLP $590,000 · 13 filings
Marshall & Popp, LLC $500,000 · 9 filings
Ogr $240,000 · 4 filings

Registrants that filed lobbying on behalf of Abbvie INC..

Clients represented

Self-filed — Abbvie INC. registers and lobbies on its own behalf, with no separate outside clients.

Issues

Issue area	Lobbied	Worked
Health Issues	106	16
Medicare/Medicaid	62	16
Taxation/Internal Revenue Code	42	16
Copyright/Patent/Trademark	25	16
Budget/Appropriations	16	1
Medical/Disease Research/Clinical Labs	12	—
Pharmacy	10	—
Labor Issues/Antitrust/Workplace	8	8
Trade (domestic/foreign)	3	3

Issue areas across Abbvie INC.'s filings, by activity count — as the client (Lobbied) and as the registrant/firm (Worked). Linked areas open the CivicGate issue page.

What they lobbied on

Reported activity from Senate LDA

FY2025 Health Issues as client

340B, transparency, prescription drug pricing and access, beneficiary access, IRA
FY2025 Medicare/Medicaid as client

Part B, Part D, drug pricing and access, negotiation
FY2025 Budget/Appropriations as client

federal budget issues
FY2025 Health Issues as client

Education and legislation related to reform of the 340(b) program.
FY2025 Medicare/Medicaid as client

Medicare Implementation of the Inflation Reduction Act.
FY2025 Taxation/Internal Revenue Code as client

Multiple tax policies, including provisions of Public Law No. 115-97 and Public Law No. 119-21.
FY2025 Health Issues as client

Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid.
FY2025 Health Issues as client

Education and legislation related to reform of the 340(b) program. Education around data privacy.

Show 52 more activities

FY2025 Medicare/Medicaid as client

Medicare Implementation of the Inflation Reduction Act. Public Law 119-21: One Big Beautiful Bill Act. Issues around drug pricing.
FY2025 Health Issues as client

Patient Access to drug treatment therapies; and drug cost and drug pricing reform. Oversight of the pharmaceutical industry and drug pricing. Monitoring policies as they relate to PBMs
FY2025 Medicare/Medicaid as client

Medicare Part D policies. Monitoring Policies related to the 340b program. Issues related to the implementation of the Inflation Reduction Act
FY2025 Pharmacy as client

Issues related to the 340B drug discount program. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169) and H.R.1, FY25 budget reconciliation.

H.R. 1
FY2025 Health Issues as client

drug pricing in federal programs, transparency, prescription drug pricing and access, beneficiary access, IRA
FY2025 Medicare/Medicaid as client

Part B, Part D, drug pricing and access, negotiation,
FY2025 Budget/Appropriations as client

federal budget issues
FY2025 Health Issues as client

Patient Access to drug treatment therapies; and drug cost and drug pricing reform. Oversight of the pharmaceutical industry and drug pricing. Policies as they relate to PBMs Issues related to the FY2026 budget and appropriations process
FY2025 Medicare/Medicaid as client

Medicare Part D policies. Monitoring Policies related to the 340b program. Issues related to the implementation of the Inflation Reduction Act Issues related to the FY2026 budget and appropriations process
FY2025 Health Issues as client

International tax issues and pharmaceutical pricing and access issues, and patent issues.
FY2025 Taxation/Internal Revenue Code as client

International tax issues and pharmaceutical pricing and access issues, and patent issues.
FY2025 Health Issues as client

International tax issues and pharmaceutical pricing and access issues, and patent issues.
FY2025 Taxation/Internal Revenue Code as client

International tax issues and pharmaceutical pricing and access issues, and patent issues.
FY2025 Pharmacy as client

Issues related to the 340B drug discount program. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169) and H.R.1, FY25 budget reconciliation.

H.R. 1
FY2025 Health Issues as client

Patient Access to drug treatment therapies; and drug cost and drug pricing reform. Oversight of the pharmaceutical industry and drug pricing. Monitoring policies as they relate to PBMs Monitor issues related to the FY2025 budget reconciliation process
FY2025 Medicare/Medicaid as client

Medicare Part D policies. Monitoring Policies related to the 340b program. Issues related to the implementation of the Inflation Reduction Act Monitor issues related to the FY2025 budget reconciliation process
FY2025 Taxation/Internal Revenue Code as client

Multiple tax policies, including provisions of the Tax Cuts and Jobs Act.
FY2025 Health Issues as client

Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid.
FY2025 Taxation/Internal Revenue Code as client

Multiple tax policies, including provisions of the Tax Cuts and Jobs Act.
FY2025 Health Issues as client

Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid.
FY2025 Health Issues as client

International tax issues and pharmaceutical pricing and access issues, and patent issues.
FY2025 Taxation/Internal Revenue Code as client

International tax issues and pharmaceutical pricing and access issues, and patent issues.
FY2025 Taxation/Internal Revenue Code as client

Multiple tax policies, including provisions of Public Law No. 115-97 and Public Law No. 119-21.
FY2025 Health Issues as client

Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid.
FY2025 Health Issues as client

Patient Access to drug treatment therapies; and drug cost and drug pricing reform. Oversight of the pharmaceutical industry and drug pricing. Monitoring policies as they relate to PBMs Monitor issues related to the FY2026 budget process
FY2025 Medicare/Medicaid as client

Medicare Part D policies. Monitoring Policies related to the 340b program. Issues related to the implementation of the Inflation Reduction Act Monitor issues related to the FY2026 budget process
FY2025 Copyright/Patent/Trademark self-filed

S.1040, Drug Competition Enhancement Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property

S. 1040
FY2025 Health Issues self-filed

S. 864, HELP Copays Act Drug cost and pricing policy issues Patient affordability issues Issues related to the 340B program

S. 864
FY2025 Medicare/Medicaid self-filed

Public Law 117-169 (formerly known as H.R. 5376, Inflation Reduction Act) Implementation regarding Medicare Part D drug negotiation program Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Issues related to HCV treatment

H.R. 5376
FY2025 Taxation/Internal Revenue Code self-filed

H.R. 1328, Supply Chain Security and Growth Act of 2025 H.R. 1990, American Innovation and R&D Competitiveness Act of 2025 H.R. 1, One Big Beautiful Bill Act Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program

H.R. 1328 H.R. 1990 H.R. 1
FY2025 Labor Issues/Antitrust/Workplace self-filed

Issues related to antitrust and competition policy
FY2025 Trade (domestic/foreign) self-filed

Issues related to pharmaceutical tariffs
FY2025 Trade (domestic/foreign) self-filed

Issues related to pharmaceutical tariffs and unfair trade practices
FY2025 Copyright/Patent/Trademark self-filed

S.1040, Drug Competition Enhancement Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property

S. 1040
FY2025 Health Issues self-filed

S. 864, HELP Copays Act Drug cost and pricing policy issues Patient affordability issues Issues related to the 340B program Issues related to data privacy

S. 864
FY2025 Medicare/Medicaid self-filed

Public Law 117-169 (formerly known as H.R. 5376, Inflation Reduction Act) Implementation regarding Medicare Part D drug negotiation program Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Issues related to HCV treatment

H.R. 5376
FY2025 Taxation/Internal Revenue Code self-filed

H.R. 1328, Supply Chain Security and Growth Act of 2025 H.R. 1990, American Innovation and R&D Competitiveness Act of 2025 Public Law No: 119-21 (formerly known as H.R. 1, One Big Beautiful Bill Act) Implementation Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program

H.R. 1328 H.R. 1990 H.R. 1
FY2025 Labor Issues/Antitrust/Workplace self-filed

Issues related to antitrust and competition policy
FY2025 Health Issues as client

Education and legislation related to reform of the 340(b) program. Education around data privacy.
FY2025 Medicare/Medicaid as client

Medicare Implementation of the Inflation Reduction Act. Public Law 119-21: One Big Beautiful Bill Act.
FY2025 Health Issues as client

International tax issues and pharmaceutical pricing and access issues, and patent issues.
FY2025 Taxation/Internal Revenue Code as client

International tax issues and pharmaceutical pricing and access issues, and patent issues.
FY2025 Health Issues as client

340B, transparency, prescription drug pricing and access, beneficiary access, IRA
FY2025 Medicare/Medicaid as client

Part B, Part D, drug pricing and access, negotiation
FY2025 Budget/Appropriations as client

federal budget issues
FY2025 Copyright/Patent/Trademark self-filed

S.1040, Drug Competition Enhancement Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property

S. 1040
FY2025 Health Issues self-filed

S. 864, HELP Copays Act H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Drug cost and pricing policy issues Patient affordability issues Issues related to the 340B program Issues related to data privacy Issues related to Hepatitis C elimination

S. 864 H.R. 4299
FY2025 Medicare/Medicaid self-filed

Public Law 117-169 (formerly known as H.R. 5376, Inflation Reduction Act) Implementation regarding Medicare Part D drug negotiation program Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Issues related to HCV treatment Issues related to Parkinsons pharmaceutical innovation

H.R. 5376
FY2025 Taxation/Internal Revenue Code self-filed

H.R. 1328, Supply Chain Security and Growth Act of 2025 H.R. 1990, American Innovation and R&D Competitiveness Act of 2025 Public Law No: 119-21 (formerly known as H.R. 1, One Big Beautiful Bill Act) Implementation Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program

H.R. 1328 H.R. 1990 H.R. 1
FY2025 Labor Issues/Antitrust/Workplace self-filed

Issues related to antitrust and competition policy
FY2025 Trade (domestic/foreign) self-filed

Issues related to pharmaceutical tariffs and unfair trade practices
FY2025 Copyright/Patent/Trademark self-filed

S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property

S. 1096

The specific issues and bills Abbvie INC. reported lobbying on, newest first. Bill references that CivicGate tracks link to the bill; others are shown as reported.